GlassScriptPhysician profile
Brian L Brown
NPI 1477082337
$12,952.98
in general payments reported to CMS, 2019-2025
64 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,561 · 2022: $2,952 · 2023: $2,858 · 2024: $2,532 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,418 · Education: $21.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,417.86 |
| Education | $21.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,674.04 | 2021-2025 | |
| Novo Nordisk INC | $1,672.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $859.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $675.74 | 2021-2025 | Otezla, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $609.37 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.75 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $496.81 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $424.71 | 2022 | |
| Pfizer INC. | $409.00 | 2023-2025 | |
| Mylan Specialty L.P. | $400.22 | 2021-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $390.09 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $337.50 | 2021-2025 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $303.47 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $296.13 | 2021 | |
| Xeris Pharmaceuticals, INC. | $280.17 | 2024-2025 | Recorlev |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $277.39 | 2022-2025 | Korlym |
| Abiomed | $267.22 | 2024-2025 | Impella |
| Amarin Pharma, INC. | $179.78 | 2021 | |
| Axsome Therapeutics, INC. | $169.26 | 2024-2025 | Auvelity, Sunosi |
| Antares Pharma, INC. | $139.84 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Therapeuticsmd, INC. | $134.35 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $128.96 | 2023-2025 | |
| Abbott Laboratories | $127.77 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Agile Therapeutics, INC. | $111.54 | 2021-2024 | Twirla |
| Glaxosmithkline, LLC. | $104.52 | 2021-2023 | Trelegy Ellipta |
| Qiagen, LLC | $99.61 | 2023-2025 | Quantiferon-Tb Gold Plus |
| Astellas Pharma US INC | $98.12 | 2023-2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $96.14 | 2022-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $94.27 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $91.97 | 2023-2024 | Xarelto, Spravato |
| Organon LLC | $91.66 | 2021-2024 | Nexplanon |
| Dexcom, INC. | $87.49 | 2023-2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $86.88 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $86.82 | 2022-2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $83.78 | 2024-2025 | Voquezna |
| Verity Pharmaceuticals INC. | $73.12 | 2025 | Tlando |
| Lundbeck LLC | $72.76 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $69.86 | 2021-2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $62.20 | 2023-2024 | Inpefa |
| Viatris Specialty LLC | $56.11 | 2025 | Yupelri |
| Halozyme INC | $52.16 | 2023 | |
| Medtronic, INC. | $51.41 | 2022-2023 | Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $48.68 | 2021-2024 | Thinprep 2000 Processor |
| Vanda Pharmaceuticals INC. | $40.05 | 2025 | Fanapt |
| Exact Sciences Corporation | $39.31 | 2024-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $35.58 | 2021 | |
| Evofem Biosciences, INC. | $35.13 | 2022 | |
| Nalu Medical, INC. | $32.02 | 2025 | Nalu Neurostimulation System |
| Recordati_rare_diseases_inc. | $30.61 | 2025 | Isturisa |
| Tempus Ai, INC | $26.61 | 2024 | |
| Nestle Healthcare Nutrition INC. | $25.04 | 2023 | |
| Coopersurgical, INC. | $23.96 | 2023 | Paragard T 380a |
| Myovant Sciences INC. | $19.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.87 | 2021 | |
| Optinose US, INC. | $18.63 | 2024 | |
| Genentech USA, INC. | $18.63 | 2021 | |
| Mimedx Group, INC. | $18.37 | 2024 | |
| Cranial Technologies, INC | $17.94 | 2023 | Doc Band |
| Seqirus USA INC | $17.09 | 2025 | Flucelvax, Fluad |
| Neurocrine Biosciences, INC. | $17.01 | 2024 | |
| Redhill Biopharma INC. | $16.31 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.30 | 2025 | Nuzyra |
| Eisai INC. | $13.97 | 2021 | |
| Tactile Systems Technology INC | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.